Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18254561 | 0.90 | SCN8A (0.51) | MEN1KMT2ASCN8AADRA1DKDM4E | |
| SCHEMBL16702793 | 0.90 | MEN1 (0.54) | MEN1KMT2AHTR6KDM4E | |
| SCHEMBL16702181 | 0.82 | SCN8A (0.47) | MEN1KMT2ASCN8AADRA1DHTR6 | |
| SCHEMBL9273372 | 0.81 | SCN8A (0.55) | MEN1KMT2ASCN8AADRA1DKDM4E | |
| SCHEMBL16709787 | 0.80 | MRGPRX4 (0.51) | MEN1KMT2AMRGPRX4MAPTNPC1 | |
| SCHEMBL18254562 | 0.79 | KMT2A (0.55) | MEN1KMT2AKDM4E | |
| SCHEMBL16702001 | 0.79 | MRGPRX4 (0.47) | MEN1KMT2ASCN8AMRGPRX4MAPT | |
| SCHEMBL16709809 | 0.78 | SMN1; SMN2 (0.54) | MEN1KMT2AMRGPRX4MAPTNPC1 | |
| SCHEMBL25314928 | 0.75 | RAB9A (0.47) | KMT2AMAPTRAB9A | |
| SCHEMBL4841298 | 0.75 | LMNA (0.47) | MAPTRAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| EP-3065738-B1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-20170275256-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-09-28 | — | — | US | disclosed |
| US-9682939-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| WO-2015069666-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | MEN1 2907/4885KMT2A 4283/4885SCN8A 3674/4885 |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | MEN1 2907/4885KMT2A 4283/4885SCN8A 3674/4885 |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | MEN1 2907/4885KMT2A 4283/4885SCN8A 3674/4885 |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | MEN1 2907/4885KMT2A 4283/4885SCN8A 3674/4885 |
| US-20170275256-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | MEN1 2907/4885KMT2A 4283/4885SCN8A 3674/4885 |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | MEN1 2907/4885KMT2A 4283/4885SCN8A 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.